



The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of the formula:




wherein X is selected from the group consisting of O and S; wherein A₁ and A₂ are individually selected from the group consisting of O, S and NH;

wherein G₁ and G₃ are C₁₋₄ alkyl chains;

wherein G₅ is a C₀₋₄ alkyl chain; and

wherein G₂ is H or



wherein A₃ is NH and A₄ is NH₂, or


-NH-G₂ forms a urea moiety;

wherein G₄ is a C₅₋₈ aryl, a C₅₋₈ arylsulfonylamino, an C₅₋₈ arylamino; and

wherein G₆ and G₇ are individually selected from the group consisting of H, F, Cl, I, Br and a C₁₋₄ alkyl, or



a salt, ester, or salt of an ester thereof.

2. (Original): The compound of claim 1, wherein X is S.
3. (Currently Amended): The compound of claim 1, wherein X is θ Q.
4. (Previously Presented): The compound of claim 1, wherein A₁ is NH.
5. (Original): The compound of claim 1, wherein A₁ is O.
6. (Previously Presented): The compound of claim 1, wherein A₂ is NH.
7. (Original): The compound of claim 1, wherein A₂ is O.
8. (Original): The compound of claim 1, wherein G₁ is a C₁ alkyl.
9. (Previously Presented): The compound of claim 1, wherein G₁ is -(CH₂)₀-.
10. (Original): The compound of claim 1, wherein G₁ is a C₂ alkyl.
11. (Original): The compound of claim 1, wherein G₁ is a C₃ alkyl.
12. (Original): The compound of claim 1, wherein G₃ is a C₁ alkyl.
13. (Original): The compound of claim 1, wherein G₃ is a C₂ alkyl.
14. (Original): The compound of claim 1, wherein G₅ is a C₁ alkyl.
15. (Original): The compound of claim 1, wherein G₅ is a C₂ alkyl.
16. (Previously Presented): The compound of claim 1, wherein G₂ is



wherein A₃ is NH and A₄ is NH₂.


17. (Cancelled):
18. (Cancelled):
19. (Previously Presented): The compound of claim 1, wherein -NH-G₂ forms a urea moiety.
20. (Cancelled):
21. (Cancelled):
22. (Original): The compound of claim 1, wherein G₄ is phenylsulfonylamino.
23. (Original): The compound of claim 1, wherein G₄ is phenyl.
24. (Original): The compound of claim 1, wherein G₆ and G₇ are halogens.
25. (Original): The compound of claim 1, wherein G₆ and G₇ are the same.
26. (Original): The compound of claim 1, wherein G₆ or G₇ are F.
27. (Currently Amended): A The compound according to ~~of~~ claim 1, wherein said compound is of further represented by the formula:



wherein X is selected from the group consisting of O and S;

G₁ and G₃ are C₁₋₄ alkyl chains;

G₂ is H or



wherein A₃ is NH and A₄ is NH₂, or

-NH-G₂ forms a urea moiety;

wherein G₄ is a C₅₋₈ aryl, a C₅₋₈ arylsulfonylamino, or a C₅₋₈ arylamino; and

wherein G₆ and G₇ are individually selected from the group consisting of H, F, Cl, I,

Br and a C₁₋₄ alkyl, or

a salt, ester, or salt of an ester thereof.

28. (Previously Presented): The compound of claim 27, wherein X is S.

29. (Previously Presented): The compound of claim 27, wherein X is O.


30. (Original): The compound of claim 27, wherein G_1 is a C_1 alkyl.

31. (Original): The compound of claim 27, wherein G_1 is a C_2 alkyl.

32. (Original): The compound of claim 27, wherein G_3 is a C_1 alkyl.

33. (Original): The compound of claim 27, wherein G_3 is a C_2 alkyl.

34. (Previously Presented): The compound of claim 27, wherein G_2 is



wherein A_3 is NH and A_4 is NH_2 .

35. (Cancelled):

36. (Cancelled):

37. (Previously Presented): The compound of claim 27, wherein $-NH-G_2$ forms a urea moiety.

38. (Cancelled):

39. (Cancelled):

40. (Previously Presented): The compound of claim 27, wherein G_4 is phenylsulfonylamino.

41. (Previously Presented): The compound of claim 27, wherein G_4 is phenyl.

42. (Cancelled):

43. (Cancelled):
44. (Original): A method of treating a solid tumor comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
45. (Original): A method of treating metastasis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
46. (Original): A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
47. (Original): A method of inhibiting fibronectin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
48. (Original): A method of inhibiting osteopontin binding comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
49. (Original): A method of treating foot and mouth disease comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
50. (Original): A method of treating osteoporosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
51. (Original): A method of treating restenosis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
52. (Original): A method of treating ocular diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.
53. (Original): A method of treating heart diseases comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

54. (Original): A method of treating arthritis comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

55. (Original): A method of treating diseases in which abnormal neovascularization occurs comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

56. (Previously Presented): A method of inhibiting α_v integrins comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

57. (Original): A method of inhibiting $\alpha_v\beta_3$ integrin comprising administering a pharmaceutically effective amount of the compound of claim 1 to a patient.

58. (Currently Amended): A pharmaceutical composition ~~for treating cancer~~ comprising a pharmaceutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier, diluent or adjuvant.

59. (Cancelled):

60. (Cancelled):

61. (Cancelled):

62. (Cancelled):

63. (Cancelled):

64. (Cancelled):

65. (Cancelled):

66. (Cancelled):

67. (Cancelled):

68. (Cancelled):

69. (Cancelled):

70. (Cancelled):

71. (Cancelled):

72. (Cancelled):

73. (Cancelled):

74. (Currently Amended): A combination ~~useful for the treatment of cancer~~ comprising at least one compound of claim 1 and at least one other anticancer agent or antiangiogenic agent.

75. (Currently Amended): A combination according to claim 74, wherein said ~~useful for the treatment of cancer comprising at least one compound of claim 1 and~~ at least one other anticancer agent is selected from the group consisting of alkylating agents, antitumor antibiotics, antimetabolites, biological agents, hormonal agents, nitrogen mustard derivatives and plant alkaloids.

76. (New): A compound selected from:

2-Benzenesulfonylamino-3-{{[5-(3-guanidino-propylcarbamoyl)-thiophene-2-carbonyl]-amino}-propionic acid, trifluoroacetic acid salt,

3-{{[5-(3-guanidino-propylcarbamoyl)-thiophene-2-carbonyl]-amino}-3-phenyl-propionic

acid,

(2S) 2-Benzenesulfonylamino-3-{{5-(2-guanidiny-ethylcarbamoyl)-thiophen-2-carbonyl}-amino propionic acid hydrochloride salt,

(2S) 2-Benzenesulfonylamino-3-(5-[2-(3-benzyl-ureido)-ethylcarbamoyl]-thiophen-2-carbonyl-amino) propionic acid,

2S-Benzenesulfonylamino-3-[(5-hydrazinocarbonyl-thiophene-2-carbonyl)-amino]-3-propionic acid trifluoroacetate,

2S-Benzenesulfonylamino-3-[(5-guanidino-aminocarbonyl-thiophene-2-carbonyl)-amino]-3-propionic acid trifluoroacetate,

(S)-3-((5-(2-Amino-ethylcarbamoyl)-furan-2-carbonyl)-amino)-2-benzenesulfonylamino-propionic acid trifluoroacetate,

(S)-2-Benzenesulfonylamino-((5-(2-guanidino-ethylcarbamoyl)-furan-2-carbonyl)-amino)-propionic acid hydrochloride,

3-{{5-(2-guanidino-ethylcarbamoyl)-thiophene-2-carbonyl}-amino}-2-(pyrimidin-2-ylamino)-propionic acid bis trifluoroacetic acid salt,

3-({5-[2-(Pyridin-2-ylamino)-ethylcarbamoyl]-thiophene-2-carbonyl}-amino)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid acetic acid salt,

2-Benzenesulfonylamino-3-({5-[(1H-benzimidazol-2-ylmethyl)-carbamoyl]-thiophene-2-carbonyl-amino)-propionic acid,

3-({5-[(6-Amino-pyridin-3-ylmethyl)-carbamoyl]-thiophene-2-carbonyl}-amino)-2-benzenesulfonylamino-propionic acid trifluoroacetic acid salt,

2-Benzenesulfonylamino-3-({5-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethylcarbamoyl]-thiophene-2-carbonyl}-amino)-propionic acid, hydrochloride salt, and

salts, esters, and salts of esters thereof.

77. (New): A method of treating a solid tumor comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.

78. (New): A method of treating metastasis comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.

79. (New): A method of inhibiting angiogenesis comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
80. (New): A method of inhibiting fibronectin binding comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
81. (New): A method of inhibiting osteopontin binding comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
82. (New): A method of treating foot and mouth disease comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
83. (New): A method of treating osteoporosis comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
84. (New): A method of treating restenosis comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
85. (New): A method of treating ocular diseases comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
86. (New): A method of treating heart diseases comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
87. (New): A method of treating arthritis comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.
88. (New): A method of treating diseases in which abnormal neovascularization occurs comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.

89. (New): A method of inhibiting α_v integrins comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.

90. (New): A method of inhibiting $\alpha_v\beta_3$ integrin comprising administering a pharmaceutically effective amount of the compound of claim 76 to a patient.

91. (New): A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 76, and a pharmaceutically acceptable carrier, diluent or adjuvant.

92. (New): A combination comprising at least one compound of claim 76 and at least one other anticancer agent or antiangiogenic agent.

93. (New): A combination according to claim 92, wherein said at least one other anticancer agent is selected from the group consisting of alkylating agents, antitumor antibiotics, antimetabolites, biological agents, hormonal agents, nitrogen mustard derivatives and plant alkaloids.